4D flow image quality with blood pool contrast: a comparison of gadofosveset trisodium and ferumoxytol
To evaluate the effect of MRI blood pool contrast agent on 4D flow image quality and ventricular volume measurements. Adult patients referred for clinical cardiac MRI (n = 22) were imaged with 4D flow. Patients with renal failure (n = 10) received ferumoxytol, and the remainder (n = 12) received gadofosveset trisodium. Image quality was assessed with (1) signal-to-noise ratio (SNR); (2) contrast-to-noise ratio (CNR); and (3) 5-point Likert scale based on endocardial border definition (1 = none; 2 = partial but unable to visualize; 3 = able to roughly estimate; 4 = visible for most of the cardiac cycle; 5 = excellent definition). A subset (n = 15) had short axis steady-state free precession (SSFP) cine imaging allowing for comparison of standard volumetric measurement technique with 4D flow derived volumetric measurements. 4D flow studies using ferumoxytol demonstrated a higher median Likert score of 5 (IQR, 5–5) versus 3 (IQR, 2–3). Median cavity SNR and CNR were higher for ferumoxytol compared to gadofosveset trisodium [65 (IQR, 50–74) versus 22 (IQR, 14–28), p < 0.001; and 40 (IQR, 32–49) versus 4 (IQR, 3–10), p < 0.001]. Good correlation (p < 0.001) was seen between SSFP and 4D flow measured ventricular volumes (ESV and EDV) with ferumoxytol (r = 0.998, mean difference = 1.2 mL, LOA = − 7.7–10.1 mL) and gadofosveset trisodium (r = 0.942, mean difference = − 2.7 mL, LOA = − 35.7–27.1 mL). Ferumoxytol used off-label as an MRI blood pool contrast agent offers an attractive alternative to gadofosveset trisodium in patients with renal failure, with excellent 4D flow image quality and good correlation of volumetric measurements compared to the CMR reference (SSFP).
KeywordsCardiac MRI 4D flow Ferumoxytol Gadolinium Image quality Volumetric analysis
Contrast to noise ratio
End diastolic volume
End systolic volume
US Food and Drug Administration
Magnetic resonance angiography
Magnetic resonance imaging
Velocity encoding range
- 4D flow
Three-dimensional, time-resolved phase contrast MRI
The authors would like to thank Christopher B. Williams (technologist) and Benjamin Mow (chief technologist) for their technical guidance and support.
Supported by NIH/NHLBI R01 HL123759 and the UCSF Department of Radiology & Biomedical Imaging Seed Grant.
Compliance with ethical standards
Conflict of interest
All authors have nothing to disclose.
- 1.Prince MR (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J X-Ray Sci Technol 11(4):231–240Google Scholar
- 14.European Medicines Agency (2017) PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations. Review finds evidence of gadolinium deposits in the brain after MRI body scans but no signs of harm. EMA/157486/2017Google Scholar